<DOC>
	<DOCNO>NCT02174718</DOCNO>
	<brief_summary>A clinical need exist non-oral vitamin D administration . This study design test new proprietary transdermal system . It look see new system safely successfully deliver vitamin D3 human .</brief_summary>
	<brief_title>Evaluation Transdermal Vitamin D3 Delivery System , D3forME</brief_title>
	<detailed_description>This conduct 3 stage . The hypothesis work follow : 1 . The D3forME topical supplement patch effectively safely raise serum 25 ( OH ) D3 human . 2 . The 25 ( OH ) D3 increment daily 4,000 IU D3forME topical supplement patch superior placebo patch . 3 . The 25 ( OH ) D3 increment daily 4,000 IU D3forME topical supplement patch non-inferior achieve 4,000 IU oral vitamin D3 daily . 4 . The 25 ( OH ) D3 increase achieve D3forME topical supplement patch differ young old adult . To test hypothesis , research conduct three stage : Stage 1 : Open Label Proof Concept Pilot Study . This study document safety tolerability daily D3forME topical supplement patch contain 4,000 IU vitamin D3 15 healthy adult men woman . The specific aim study : 1 . Document change serum 25 ( OH ) D3 daily transdermal vitamin D3 dose 4,000 IU use D3forME topical supplement patch . 2 . Evaluate safety skin tolerability D3forME topical supplement patch . Stage 2 : Efficacy study . In randomized , double blind placebo control study four month duration involve 40 healthy adult men woman ( n = 20 per group ) specific aim : 1 . Evaluate safety efficacy daily D3forME topical supplement patch increase serum 25 ( OH ) D3 . 2 . Determine 25 ( OH ) D3 increase achieve 4,000 IU daily D3forME topical supplement patch superior placebo . Stage 3 : Non-inferiority study . In randomized , double blind placebo control study six month duration involve 220 healthy adult men woman two age cohort , ( 18-40 year 65-85 year ) , specific aim : 1 . Determine 25 ( OH ) D3 increase achieve 4,000 IU daily D3forME topical supplement patch inferior achieve 4,000 IU oral vitamin D3 supplementation . 2 . Assess 25 ( OH ) D3 increase achieve daily D3forME topical supplement patch differs young old adult . As exploratory endpoint , potential effect body fat response daily D3forME topical supplement patch evaluate use DXA measure body composition efficacy non-inferiority study ( stage 2 3 ) . Open-label Proof Concept Pilot Study . This open label study evaluate safety daily D3forME topical supplement patch contain 4,000 IU vitamin D3 . Additionally , begin evaluate efficacy approach serum 25 ( OH ) D3 . This pilot study include 15 healthy community dwell men woman age 18-75 year without condition contraindicate D supplementation know skin condition could potentially interfere cutaneous vitamin D3 delivery . Volunteers recruit Madison , WI area . Stage 2 : Randomized Double-blind , Placebo Controlled Efficacy Study : This study include 40 adult ( n = 20 group ) use inclusion/exclusion criterion Stage 3 : Non-inferiority Study : This phase include 220 adult randomly assign one three treatment arm : n = 100 transdermal patch/placebo oral , n = 100 oral supplementation/placebo patch n = 20 placebo oral placebo patch ) use inclusion/exclusion criterion note , except age , limited 18-40 65-85 . Additionally , treatment arm equally divide two cohort , `` young ; '' age 18-40 `` old ; '' age 65-85 year .</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Healthy , communitydwelling ambulatory adult Able willing sign inform consent Age 18 75 year Baseline serum 25OHD concentration &gt; 10 ng/mL &lt; 50 ng/mL Not pregnant Willing alter amount baseline vitamin D supplementation course study Willing utilize sunscreen SPF15 high sun exposure 15 minute expect Current hypercalcemia ( serum calcium &gt; 10.5 mg/dl ) untreated primary hyperparathyroidism History nephrolithiasis Baseline 24hour urine calcium &gt; 250 mg ( female ) 300 mg ( male ) Known risk factor hypercalcemia , e.g. , malignancy , tuberculosis , sarcoidosis History form cancer within past five year exception adequately treat squamous cell basal cell skin carcinoma Renal failure ; define calculate creatinine clearance ( use CockroftGault approach ) ≤ 35 ml/minute Severe endorgan disease , e.g. , cardiovascular , hepatic , hematologic , pulmonary , etc. , might limit ability complete study Treatment drug know interfere vitamin D metabolism , e.g. , phenytoin , phenobarbital Known cutaneous sensitivity/allergy tape adhesives Known skin disease , e.g. , psoriasis , pemphigus , etc , might alter transdermal vitamin D absorption Treatment high dose vitamin D ( ≥ 50,000 IU weekly ) active metabolite vitamin D , e.g. , calcitriol , within six month screen Use tan bed salon unwillingness utilize sunscreen period sun exposure 15 minute longer Planned trips/vacations likely associate substantial amount sun exposure course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cholecalciferol</keyword>
	<keyword>Transdermal patch</keyword>
</DOC>